Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGAINST-PLD Study of leuprorelin in severe polycystic liver disease
NL-OMON59521Phase 3Completed
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leuprolide in Polycystic liver disease (PLD), sponsored by University Medical Center Groningen. Started Oct 2024; status: completed.
02
Drugs
leuprolide
03
Conditions
Polycystic liver disease (PLD)
Beyond the preview
Go deeper on NL-OMON59521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59521.